Oxford’s Brainomix joins CEO Roundtable on Cancer

Oxford-based AI imaging company Brainomix has been announced as the newest member of the CEO Roundtable on Cancer.

The non-profit organisation, which began in 2001 following the vision of former US President George H.W. Bush, aims to develop and establish initiatives aimed at reducing the risk of cancer, enabling early diagnosis, facilitating access to the best available treatments, and hastening the discovery of novel and more effective oncology therapies.

Brainomix is the first AI imaging company to join an organisation which includes some of the world’s leading cancer research institutions, pharmaceutical companies, and government officials. This multidisciplinary international group serves as a convener, collaborator and catalyst focused on eliminating cancer as a personal disease and public health problem.

Read more - Brainomix gets FDA clearance for stroke AI imaging software

The company specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke, lung fibrosis, and cancer.

Dr Michalis Papadakis, CEO and Co-Founder of Brainomix, said: “We are honoured and excited to have the opportunity to join the CEO Roundtable on Cancer, an organization working tirelessly to reduce the burden of cancer around the world.

“By leveraging our expertise in AI and our track record in developing novel imaging-based solutions, we believe we can contribute towards the impressive work that the organization is already doing in the fight against cancer.”

William Louv, PhD, CEO of the CEO Roundtable on Cancer said “We are pleased to welcome Brainomix to the Roundtable. Its insights into how AI can aid both research and treatment will be incredibly valuable as we strive to reduce the burden of cancer globally.”

Read more - Brainomix involved in new UK atrial fibrillation study